Pharmaceutical composition containing empagliflozin and application thereof
Patent Information
- Application Number
- CN202410254242.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-11-10
- Filing Date
- 2017-03-13
- Publication Date
- 2024-11-08
AI Technical Summary
目前没有适应HFpEF的有效治疗,治疗侧重于症状管理和合并症
[0327] Pharmaceutical compositions and methods according to the present invention exhibit beneficial effects in the treatment and prevention of those diseases and conditions described above. For example, beneficial effects may be seen in terms of efficacy, dose intensity, dose frequency, pharmacodynamic properties, pharmacokinetic properties, fewer side effects, convenience, compliance, etc.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_6
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201780018512.2 (invention name: pharmaceutical composition containing empagliflozin and use thereof; application date: March 13, 2017). Technical Field
[0002] The present invention relates to a method for treating chronic heart failure, reducing the risk of cardiovascular death, reducing the risk of hospitalization for heart failure, reducing all-cause mortality, reducing the risk of all-cause hospitalization, reducing the risk of new atrial fibrillation, and improving health-related quality of life and / or subjective functional capacity in patients with chronic heart failure. The present invention also relates to a method for treating, preventing, preventing, reducing the risk of acute heart failure or delaying the occurrence of acute heart failure, wherein the acute heart failure includes acute decompensated heart failure. In addition, the present invention relates to a method for improving renal function and for treating or preventing certain renal disorders and diseases in patients with chronic heart failure. The present invention further relates to empagliflozin (also translated as "empagliflozin"), which is used in a method for treating and / or preventing certain diseases or conditions, or reducing the risk of certain diseases or conditions, or delaying the occurrence of certain diseases or conditions in patients with chronic heart failure. Background Art
[0003] Heart failure (HF) is a clinical syndrome caused by the inability of the heart to provide adequate blood supply or to maintain adequate blood supply at the expense of elevated left ventricular (LV) filling pressure. Patients with heart failure (HF) are poorly diagnosed, and approximately 50% of patients die from HF within 5 years. Approximately 66% of patients with HF are non-diabetic. In 2013, the total prevalence of HF worldwide was 26 million. In the United States, more than 1 million HF hospitalizations occur each year. There is a considerable unmet need in HF. The overall goal of treating HF is to prevent hospitalization and death, control symptoms, and improve quality of life. There are two types of HF: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the latter representing 50% of total HF. Both HFrEF and HFpEF are associated with high morbidity and mortality. Existing treatment options for HFrEF are mainly based on the administration of β-blockers, ACEi, ARB, ARNi, MRA, and diuretics. Despite these options, the results are still not optimal. There are currently no effective treatments for HFpEF, and treatment focuses on symptom management and comorbidities.
[0004] Therefore, there is an unmet medical need for methods for treating chronic heart failure, particularly in patients with HFrEF or HFpEF, that have good efficacy with respect to disease-modifying properties and with respect to reducing the risk of mortality and hospitalization while showing a good safety profile. Summary of the invention
[0005] The present invention relates to a method for treating, preventing, preventing or delaying the onset of chronic heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient.
[0006] The present invention also relates to a method for reducing the risk of cardiovascular death in a patient suffering from chronic heart failure, the method comprising administering empagliflozin to the patient.
[0007] Furthermore, the present invention relates to a method for reducing the risk of hospitalization (first and recurrent) for heart failure in a patient with chronic heart failure, said method comprising administering empagliflozin to said patient.
[0008] Furthermore, the present invention relates to a method for reducing all-cause mortality in patients with chronic heart failure, the method comprising administering empagliflozin to the patients.
[0009] Furthermore, the present invention relates to a method for reducing the risk of all-cause hospitalization in a patient with chronic heart failure, said method comprising administering empagliflozin to said patient.
[0010] The present invention also relates to a method for reducing the risk of new onset of atrial fibrillation in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0011] The present invention also relates to a method for treating, preventing, protecting against, reducing the risk of, or delaying the onset of acute heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient.
[0012] The present invention also relates to a method for treating, preventing, protecting against, reducing the risk of, or delaying the onset of acute decompensated heart failure (ADHF) in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0013] The present invention also relates to a method for preventing, slowing or reversing the progression to macroalbuminuria in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0014] The present invention also relates to a method for improving renal function or renal protection in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0015] The present invention also relates to a method for treating, preventing, protecting against, reducing the risk of chronic kidney disease in patients with chronic heart failure, delaying the onset of chronic kidney disease in patients with chronic heart failure and / or delaying the progression of chronic kidney disease in patients with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0016] The present invention also relates to a method for improving health-related quality of life and / or subjective functional capacity in a patient suffering from chronic heart failure, the method comprising administering empagliflozin to the patient.
[0017] The present invention further provides empagliflozin or a pharmaceutical composition for use as a medicament in any of the methods described herein, the composition comprising empagliflozin, optionally in combination with one or more other therapeutic substances.
[0018] The present invention further provides empagliflozin or a pharmaceutical composition for use in a method for treating, preventing or reducing the risk of any of the diseases or conditions described herein, the composition comprising empagliflozin, optionally in combination with one or more other therapeutic substances.
[0019] The present invention further provides empagliflozin or a pharmaceutical composition for the preparation of a medicament for use in any of the methods described herein, the composition comprising empagliflozin, optionally in combination with one or more other therapeutic substances.
[0020] In one embodiment, the present invention provides a method of treatment comprising:
[0021] a) identifying patients in need of treatment for chronic heart failure; and
[0022] b) administering empagliflozin to the patient.
[0023] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0024] a. Determine symptoms according to the patient's NYHA classification;
[0025] b. Identifying that the patient suffers from chronic heart failure according to NYHA class I;
[0026] c. administering empagliflozin to the patient.
[0027] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0028] a. Determine symptoms according to the patient's NYHA classification;
[0029] b. Identifying that the patient suffers from chronic heart failure according to NYHA class II;
[0030] c. administering empagliflozin to the patient.
[0031] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0032] a. Determine symptoms according to the patient's NYHA classification;
[0033] b. Identifying that the patient suffers from chronic heart failure according to NYHA class III;
[0034] c. administering empagliflozin to the patient.
[0035] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0036] a. Determine symptoms according to the patient's NYHA classification;
[0037] b. Identifying that the patient suffers from chronic heart failure according to NYHA IV grade;
[0038] c. administering empagliflozin to the patient.
[0039] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0040] a. Determining the patient's ejection fraction;
[0041] b. Identifying that the patient has an ejection fraction equal to or less than 40%;
[0042] c. administering empagliflozin to the patient.
[0043] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0044] a. Determine symptoms according to the patient's NYHA classification;
[0045] b. determining the patient's ejection fraction;
[0046] c. Identifying that the patient suffers from chronic heart failure according to NYHAI grade and an ejection fraction equal to or less than 40%;
[0047] d. administering empagliflozin to the patient.
[0048] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0049] a. Determine symptoms according to the patient's NTHA classification;
[0050] b. determining the patient's ejection fraction;
[0051] c. Identifying that the patient suffers from chronic heart failure according to NYHA class II, III or IV and an ejection fraction equal to or less than 40%;
[0052] d. administering empagliflozin to the patient.
[0053] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0054] a. Determine symptoms according to the patient's NYHA classification;
[0055] b. determining the patient's ejection fraction;
[0056] c. Identifying that the patient suffers from chronic heart failure according to NYHA class I and an ejection fraction greater than 40%, in particular greater than 50%;
[0057] d. administering empagliflozin to the patient.
[0058] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0059] a. Determine symptoms according to the patient's NYHA classification;
[0060] b. determining the patient's ejection fraction;
[0061] c. Identifying that the patient suffers from chronic heart failure according to NYHA class II, III or IV and an ejection fraction greater than 40%, in particular greater than 50%;
[0062] e. administering empagliflozin to the patient.
[0063] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0064] a. Determine symptoms according to the patient's NYHA classification;
[0065] b. determining the patient's ejection fraction;
[0066] c. determining the BNP or NT-proBNP value of the patient;
[0067] d. identifying that said patient suffers from chronic heart failure according to said NYHA class I and an ejection fraction equal to or less than 40%, in particular greater than 50%, and said patient has an elevated BNP or NT-proBNP value;
[0068] e. administering empagliflozin to the patient.
[0069] In one embodiment, the present invention provides a method for treating chronic heart failure in a patient, the method comprising:
[0070] a. Determine symptoms according to the patient's NYHA classification;
[0071] b. determining the patient's ejection fraction;
[0072] c. determining the BNP or NT-proBNP value of the patient;
[0073] d. identifying that the patient suffers from chronic heart failure according to NYHA class II, III or IV and an ejection fraction equal to or less than 40%, in particular greater than 50%, and that the patient has an elevated BNP or NT-proBNP value;
[0074] e. administering empagliflozin to the patient.
[0075] According to this embodiment, an elevated BNP or NT-proBNP value is in particular a BNP value equal to or greater than 150 pg / mL or a NT-proBNP value equal to or greater than 600 pg / mL. Furthermore, according to this embodiment, if the patient has been hospitalized for heart failure within the past 9 months, an elevated BNP or NT-proBNP value is in particular a BNP value equal to or greater than 100 pg / mL or a NT-proBNP value equal to or greater than 400 pg / mL.
[0076] In the methods according to the present invention, empagliflozin is optionally administered to a patient in combination with one or more other therapeutic substances.
[0077] Other aspects of the present invention will become apparent to those skilled in the art from the above and below descriptions and examples.
[0078] definition
[0079] The term "active ingredient" of the pharmaceutical composition according to the present invention means the SGLT2 inhibitor empagliflozin according to the present invention. "Active ingredient" is sometimes also referred to as "active substance" in the present application.
[0080] The term "body mass index" or "BMI" for a human patient is defined as the weight in kilograms divided by the square of the height in meters, such that the units of BMI are kg / m2 .
[0081] The term "overweight" is defined as an individual with a BMI equal to or greater than 25 kg / m 2 And less than 30kg / m 2 The terms "overweight" and "pre-obese" are used interchangeably.
[0082] The term "obesity" or "being obese" is defined as an individual with a BMI equal to or greater than 30 kg / m 2 According to the WHO definition, the term obesity can be classified as follows: The term "class I obesity" is a BMI equal to or greater than 30 kg / m 2 But less than 35kg / m 2 The term "class II obesity" is a BMI equal to or greater than 35 kg / m 2 But less than 40kg / m 2 The term "class III obesity" is a BMI equal to or greater than 40 kg / m 2 situation.
[0083] Indications for obesity include, in particular, exogenous obesity, hyperinsulinemic obesity, hyperplastic obesity, pituitary obesity (hyperphyseal adiposity), protoplasmic hyperplastic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, dietary obesity, hypogonadal obesity, central obesity, visceral obesity, and abdominal obesity.
[0084] The term "visceral obesity" is defined as a waist-to-hip ratio greater than or equal to 1.0 for men and 0.8 for women. Visceral obesity defines the risk of insulin resistance and the development of prediabetes.
[0085] The term "abdominal obesity" is generally defined as a waist circumference of >40 inches or 102 cm in men and >35 inches or 94 cm in women. For Japanese patients, abdominal obesity can be defined as a waist circumference of ≥85 cm in men and ≥90 cm in women (see, e.g., the Japanese Committee for the Study of Diagnostic Criteria for Metabolic Syndrome).
[0086] The term "normoglycemia" is defined as a condition in which a subject's fasting blood glucose concentration is within the normal range, ie, greater than 70 mg / dL (3.89 mmol / L) and less than 100 mg / dL (5.6 mmol / L). The wording "fasting" has the usual meaning of medical terminology.
[0087] The term "hyperglycemia" is defined as a condition in which a subject's fasting blood glucose concentration is above the normal range, ie, greater than 100 mg / dL (5.6 mmol / L). The wording "fasting" has the usual meaning of a medical term.
[0088] The term "hypoglycemia" is defined as a condition in which a subject's blood glucose concentration is below the normal range, specifically below 70 mg / dL (3.89 mmol / L).
[0089] The term "postprandial hyperglycemia" is defined as a condition in which a subject's blood glucose or serum glucose concentration is greater than 200 mg / dL (11.11 mmol / L) 2 hours after a meal.
[0090] The term "impaired fasting glucose" or "IFG" is defined as a subject having a fasting blood glucose concentration or fasting serum glucose concentration ranging from 100 to 125 mg / dL (i.e., from 5.6 to 6.9 mmol / L), particularly greater than 110 mg / dL and less than 126 mg / dL (7.00 mmol / L). A subject with "normal fasting glucose" has a fasting glucose concentration of less than 100 mg / dL, i.e., less than 5.6 mmol / L.
[0091] The term "impaired glucose tolerance" or "IGT" is defined as a condition in which a subject has a 2-hour postprandial blood glucose or serum glucose concentration greater than 140 mg / dL (7.78 mmol / L) and less than 200 mg / dL (11.11 mmol / L). Abnormal glucose tolerance can be measured as the 2-hour postprandial blood glucose or serum glucose concentration as the blood glucose level in mg of glucose per dL of plasma 2 hours after taking 75 g of glucose after fasting. A subject with "normal glucose tolerance" has a 2-hour postprandial blood glucose or serum glucose concentration less than 140 mg / dL (7.78 mmol / L).
[0092] The term "hyperinsulinemia" is defined as an elevation of fasting or postprandial serum or plasma insulin concentrations in a subject with insulin resistance (either normoglycemic or not) above that of a normal lean individual without insulin resistance and with a waist-to-hip ratio of <1.0 (male) or <0.8 (female).
[0093] The terms "insulin sensitizing", "improving insulin resistance" or "reducing insulin resistance" are synonymous and used interchangeably.
[0094] The term "insulin resistance" is defined as a state in which circulating insulin levels that exceed the normal response to a glucose load are required to maintain a normoglycemic state (Ford ES, et al. JAMA. (2002)
[0095] 287:356-9). A method for determining insulin resistance is the euglycaemic-hyperinsulinaemic clamp test. The ratio of insulin to glucose is determined within the context of a combined insulin-glucose infusion technique. Insulin resistance is found (WHO definition) if glucose absorption is below the 25th percentile of the background population studied. Less laborious than the clamp test is the so-called minimal model, in which the insulin and glucose concentrations in the blood are measured at fixed time intervals during an intravenous glucose tolerance test and the insulin resistance is calculated from this. Using this method, it is not possible to distinguish between hepatic and peripheral insulin resistance.
[0096] In addition, insulin resistance, the response of insulin resistant patients to treatment, insulin sensitivity and hyperinsulinemia can be quantified by evaluating the "homeostatic model assessment of insulin resistance index (HOMA-IR)" score (a reliable indicator of insulin resistance) (Katsuki A, et al. Diabetes Care 2001; 24: 362-5). Further reference is made to the HOMA index for determining insulin sensitivity (Matthews et al., Diabetologia 1985, 28: 412-19), the method for determining the ratio of intact proinsulin to insulin (Forst et al., Diabetes 2003, 52 (Suppl. 1): A459) and further reference is made to the normal blood sugar clamp study. In addition, plasma adiponectin levels can be detected as a potential surrogate for insulin sensitivity. The score for evaluating the insulin resistance homeostatic model assessment of insulin resistance index (HOMA)-IR is calculated using the formula (Galvin P, et al. Diabet Med 1992; 9: 921-8):
[0097] HOMA-IR = [fasting serum insulin (μU / mL)] × [fasting blood glucose (mmol / L) / 22.5]
[0098] Insulin resistance in these individuals can be determined by calculating a HOMA-IR score. For purposes of the present invention, insulin resistance is defined as clinical symptoms in which an individual has a HOMA-IR score > 4.0 or a HOMA-IR score above the upper limit of normal as defined by the laboratory performing the glucose and insulin measurements.
[0099] Typically, other parameters are used in daily clinical practice to assess insulin resistance. Preferably, for example, the patient's triglyceride concentration is used, since elevated triglyceride levels are significantly associated with the presence of insulin resistance.
[0100] Individuals who are likely to have insulin resistance are those who have two or more of the following attributes: 1) overweight or obesity, 2) hypertension, 3) hyperlipidemia, 4) one or more first-degree relatives diagnosed with IGT or IFG or type 2 diabetes.
[0101] Patients with a predisposition to the development of IGT or IFG or type 2 diabetes are those normoglycemic patients who have hyperinsulinemia and, by definition, are insulin resistant. Patients with typical insulin resistance are usually overweight or obese. If insulin resistance can be detected, this is a particularly strong indication of the presence of prediabetes. Therefore, it is likely that these people require 2-3 times more insulin than healthy people in order to maintain glucose homeostasis before any clinical symptoms will occur.
[0102] "Prediabetes" is a general term that refers to the intermediate stage between normal glucose tolerance (NGT) and overt type 2 diabetes (T2DM), also known as intermediate hyperglycemia. Therefore, in one aspect of the present invention, if HbA1c is greater than or equal to 5.7% and less than 6.5%, the individual is diagnosed with "prediabetes". According to another aspect of the present invention, "prediabetes" represents 3 groups of individuals, those individuals with impaired glucose tolerance (IGT) alone, those individuals with impaired fasting glucose (IFG) alone, or those individuals with both IGT and IFG. IGT and IFG usually have different pathophysiological causes, however, mixed conditions with characteristics of both may also exist in patients. Therefore, in another aspect of the present invention, a patient diagnosed with "prediabetes" is an individual diagnosed with IGT or diagnosed with IFG or diagnosed with both IGT and IFG. According to the definition of the American Diabetes Association (ADA) and in the context of aspects of the present invention, a patient diagnosed with "prediabetes" is an individual with the following characteristics:
[0103] a) Fasting plasma glucose (FPG) concentration <100 mg / dL [1 mg / dL = 0.05555 mmol / L]; and 2-hour plasma glucose (PG) concentration, as measured by a 75 g oral glucose tolerance test (OGTT), ranges between ≥140 mg / dL and <200 mg / dL (i.e., IGT); or
[0104] b) Fasting blood glucose (FPG) concentration ≥100 mg / dL and <126 mg / dL; and 2-hour blood glucose (PG)
[0105] Concentration, as determined by a 75 g oral glucose tolerance test (OGTT) < 140 mg / dL (i.e.,
[0106] IFG);
[0107] c) Fasting blood glucose (FPG) concentration ≥100 mg / dL and <126 mg / dL; and 2-hour blood glucose (PG)
[0108] Concentration, measured by a 75 g oral glucose tolerance test (OGTT) in the range of ≥140
[0109] mg / dL and <200 mg / dL (ie, both IGT and IFG).
[0110] Patients with "prediabetes" are individuals who are predisposed to develop type 2 diabetes. Prediabetes expands the definition of IGT to include individuals whose fasting blood glucose range is within the high normal range of ≥100 mg / dL (JB Meigs, et al. Diabetes 2003; 52: 1475-1484). The scientific and medical basis for identifying prediabetes as a serious health threat is published in a position statement entitled "Preventing or Delaying Type 2 Diabetes" jointly issued by the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases (Diabetes Care 2002; 25: 742-749).
[0111] The methods used to study pancreatic β-cell function are similar to those described above for insulin sensitivity, hyperinsulinemia or insulin resistance: for example, improvements in β-cell function are measured by determining the HOMA-index (homeostasis model assessment) of β-cell function, HOMA-B (Matthews et al., Diabetologia 1985, 28:412-19), the ratio of intact proinsulin to insulin (Forstet al., Diabetes 2003, 52(Suppl. 1):A459), first and second phase insulin secretion after an oral glucose tolerance test or a meal tolerance test (Stumvoll et al., Diabetes care 2000, 23:295-301), insulin / C-peptide secretion after an oral glucose tolerance test or a meal tolerance test, or by using hyperglycemic clamp studies and / or minimal modeling (Stumvoll et al., Eur J Clin Invest 2001, 31:380-81) after a frequently sampled intravenous glucose tolerance test.
[0112] The term "type 1 diabetes" is defined as a condition in which a subject has a fasting blood sugar or serum glucose concentration greater than 125 mg / dL (6.94 mmol / L) in the presence of autoimmunity to pancreatic beta cells or insulin. If a glucose tolerance test is performed, the blood sugar level of a diabetic patient will exceed 200 mg glucose per dL (1.11 mmol / L) of plasma 2 hours after fasting ingestion of 75 g of glucose in the presence of autoimmunity to pancreatic beta cells or insulin. In a glucose tolerance test, 75 g of glucose is orally administered to the patient to be tested after fasting for 10-12 hours, and the blood sugar level is recorded immediately before ingestion of the glucose and 1 and 2 hours after ingestion. The presence of autoimmunity against pancreatic beta cells can be observed by detecting circulating islet cell autoantibodies ["type 1A diabetes"], i.e., at least one of the following antibodies: GAD65 [glutamic acid decarboxylase-65], ICA [islet cell cytoplasm], IA-2 [intracytoplasmic domain of tyrosine phosphatase-like protein IA-2], ZnT8 [zinc transporter-8], or anti-insulin; or other signs of autoimmunity in the absence of typical circulating autoantibodies [type 1B diabetes], i.e., as detected by pancreatic biopsy or imaging). Genetic susceptibility is usually present (e.g., HLA, INS VNTR, and PTPN22), but not always.
[0113] The term "type 2 diabetes" or "T2DM" is defined as a condition in which a subject has a fasting blood glucose or serum glucose concentration greater than 125 mg / dL (6.94 mmol / L). The determination of blood glucose values is a standard procedure in routine medical analysis. If a glucose tolerance test is performed, the blood glucose level of a diabetic patient will exceed 200 mg of glucose per dL (11.1 mmol / l) of plasma 2 hours after taking 75 g of glucose on a fasting stomach. In a glucose tolerance test, 75 g of glucose is orally administered to the patient to be tested after fasting for 10-12 hours, and the blood glucose level is recorded immediately before taking glucose and 1 and 2 hours after taking glucose. In healthy subjects, the blood glucose level will be between 60 and 110 mg per dL of plasma before taking glucose, less than 200 mg per dL 1 hour after taking glucose, and less than 140 mg per dL 2 hours after taking glucose. If the value is between 140 and 200 mg after 2 hours, it is considered to be abnormal glucose tolerance.
[0114] The term "advanced stage of type 2 diabetes" includes patients with secondary drug failure, indications for insulin therapy, and progression to microvascular and macrovascular complications such as diabetic nephropathy or coronary heart disease (CHD).
[0115] The term "LADA" ("latent autoimmune diabetes in adults") refers to patients who are clinically diagnosed with type 2 diabetes but are detected to have autoimmunity against pancreatic β cells. Latent autoimmune diabetes in adults (LADA) is also known as chronic progressive type 1 diabetes (T1DM), "mild" T1DM, non-insulin dependent type 1 DM, 1 1 / 2 type DM, dual diabetes or antibody positive type 2 diabetes (T2DM). LADA is usually not clearly defined, and in contrast to T1DM, due to rapidly progressive β cell failure, rarely or never presents significant weight loss and ketoacidosis.
[0116] The term "HbA1c" refers to the non-enzymatic glycation product of the B chain of hemoglobin, the determination of which is well known to those skilled in the art. In monitoring diabetes therapy, the HbA1c value is extremely important. Since its production depends essentially on the blood glucose level and the life span of the red blood cells, HbA1c in the sense of "blood glucose memory" reflects the average blood glucose level of the previous 4-6 weeks. Diabetic patients whose HbA1c values are always well adjusted (i.e. <6.5% of the total hemoglobin in the sample) by intensive diabetes therapy are significantly better protected from diabetic microangiopathy. For example, metformin itself achieves an average improvement of about 1.0-1.5% in the HbA1c values of diabetic patients. In all diabetic patients, this reduction in HbA1C values is not sufficient to reach the desired target range of <7% or <6.5%, preferably <6% HbA1c.
[0117] The term "inadequate glycemic control" or "inadequate glycemic control" within the scope of the present invention means situations in which patients show HbA1c values above 6.5%, in particular above 7.0%, even more preferably above 7.5%, in particular above 8%.
[0118] The term "metabolic syndrome", also known as "Syndrome X" (used in the context of metabolic disorders), also known as "metabolic disorder syndrome", is a complex of syndromes characterized primarily by insulin resistance (Laaksonen DE, et al. Am J Epidemiol 2002; 156: 1070-7). According to the ATP III / NCEP guidelines (Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Panel on the Detection, Evaluation and Treatment of Hyperlipidemic Cholesterol in Adults (Adult Treatment Panel III) JAMA: Journal of the American Medical Association (2001) 285: 2486-2497), a diagnosis of metabolic syndrome is made when three or more of the following risk factors are present:
[0119] 1. Abdominal obesity, defined as waist circumference >40 inches or 102 cm for men and >35 inches or 94 cm for women; or for Japanese patients, abdominal obesity defined as waist circumference ≥85 cm for men and ≥90 cm for women;
[0120] 2. Triglycerides: ≥150 mg / dL
[0121] 3. Male HDL cholesterol <40 mg / dL
[0122] 4. Blood pressure ≥130 / 85 mm Hg (SBP ≥130 or DBP ≥85)
[0123] 5. Fasting blood glucose ≥100 mg / dL
[0124] The NCEP definition has been confirmed (Laaksonen DE, et al. Am J Epidemiol. (2002) 156: 1070-7). Triglycerides and HDL cholesterol in blood can also be determined by standard methods in medical analysis, for example as described in Thomas L (editor): "Labor und Diagnose", TH-Books Verlagsgesellschaft mbH, Frankfurt / Main, 2000.
[0125] According to the commonly used definition, hypertension is diagnosed if the systolic blood pressure (SBP) exceeds a value of 140 mm Hg and the diastolic blood pressure (DBP) exceeds a value of 90 mm Hg. If the patient has overt diabetes, it is currently recommended to reduce the systolic blood pressure to a level below 130 mm Hg and the diastolic blood pressure to below 80 mm Hg.
[0126] The term "empagliflozin" refers to an SGLT2 inhibitor, such as 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene of the following formula as described in WO 2005 / 092877:
[0127]
[0128] Methods of synthesis are described in the literature, for example WO 06 / 120208 and WO 2011 / 039108. According to the present invention, it is understood that the definition of Empagliflozin also includes its hydrates, solvates and polymorphs thereof, and prodrugs thereof. Favorable crystalline forms of Empagliflozin are described in WO 2006 / 117359 and WO 2011 / 039107, which are hereby incorporated by reference in their entirety. This crystalline form has good solubility, which enables the SGLT2 inhibitor to have good bioavailability. In addition, the crystalline form is physicochemically stable and therefore provides good shelf life stability of the pharmaceutical composition. Preferred pharmaceutical compositions, such as solid preparations for oral administration, such as tablets, are described in WO2010 / 092126, which is hereby incorporated into the present application in its entirety.
[0129] The terms "treatment" and "treating" include therapeutic treatment of a patient who has already developed (particularly in an overt form) the condition. Therapeutic treatment may be symptomatic treatment to relieve the symptoms of a particular indication, or causal treatment to reverse or partially reverse the condition of the indication or to stop or slow the progression of the disease. Thus the methods and compositions of the invention may be used for therapeutic treatment as well as chronic treatment over a period of time.
[0130] The terms "prophylactically treating," "preventivally treating," and "prevention" are used interchangeably and include treating a patient at risk of developing the above-mentioned conditions, thereby reducing said risk.
[0131] The term "tablet" includes uncoated tablets and tablets with one or more coatings. In addition, the term "tablet" includes tablets with one, two, three or even more layers and compressed coated tablets, wherein each of the above tablet types may have no or one or more coatings. The term "tablet" also includes mini tablets, melting tablets, chewable tablets, effervescent tablets and orodisintegrating tablets.
[0132] The terms "pharmacopoe" and "pharmacopoeias" refer to standard pharmacopoeias, such as "USP 31 - NF 26 to Second Appendix" (United States Pharmacopoeial Convention) or "European Pharmacopoeia 6.3" (European Directorate for the Quality of Medicines and Health, 2000-2009).
[0133] The term "chronic heart failure" or "CHF" is a synonym for congestive heart failure (CCF). The degree of heart failure can be graded according to the New York Heart Association (NYHA) functional classification and includes NYHA class I, II, III and IV. Chronic heart failure can be distinguished based on whether it affects the left ventricle's ability to contract (heart failure with reduced ejection fraction) or affects the heart's ability to relax (heart failure with preserved ejection fraction).
[0134] The term "HFpEF" refers to heart failure with preserved ejection fraction. HFpEF is also sometimes called "diastolic heart failure."
[0135] The term "HFrEF" refers to heart failure with reduced ejection fraction. HFrEF is also sometimes called "systolic heart failure."
[0136] The term "LVEF" refers to left ventricular ejection fraction. The ejection fraction can be obtained by echocardiography, radionuclide ventriculography and angiography, preferably by echocardiography.
[0137] The term "BNP" refers to brain natriuretic peptide, also known as B-type natriuretic peptide. BNP is used to screen and diagnose chronic heart failure. BNP values are determined in plasma and serum.
[0138] The term "NT-proBNP" refers to the N-terminal end of the prohormone brain natriuretic peptide. NT-proBNP is used for screening and diagnosis of chronic heart failure. NT-proBNP values are determined in plasma and serum.
[0139] The term "albuminuria" is defined as a condition in which there is an excess of normal amounts of albumin in the urine. Albuminuria can be determined by the albumin excretion rate (AER) and / or the albumin-creatine ratio (ACR, also known as UACR) in the urine. The categories of albuminuria in CKD are defined as follows:
[0140]
[0141] Category A1 reflects acalbuminuria, category A2 reflects microalbuminuria, and category A3 shows macroalbuminuria. Progression of category A1 usually leads to microalbuminuria (A2), but may also lead directly to macroalbuminuria (A3). Progression of microalbuminuria (A2) leads to macroalbuminuria (A3).
[0142] The term "eGFR" refers to the estimated glomerular filtration rate (GFR). The GFR describes the flow rate of filtered fluid through the kidneys. The GFR can be estimated based on the serum creatinine value, for example using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the Cockcroft-Gault formula, or the Modification of Diet in Renal Disease (MDRD) formula, which are all known in the art.
[0143] According to aspects of the present invention, the estimated glomerular filtration rate (eGFR) is derived from serum creatinine value, age, gender, etc., based on the CKD-EPI equation:
[0144] GFR = 141 × min (S cr / κ,1) α ×max(S cr / κ,1) -1.209 ×0.993 年龄 ×1.018[if female]×1.159[if black]
[0145] in:
[0146] Scr is serum creatinine, expressed in mg / dL.
[0147] κ is 0.7 for females and 0.9 for males,
[0148] α is -0.329 for females and -0.411 for males,
[0149] min means S cr / κ minimum or 1, and
[0150] max represents S cr / κ is the maximum value or 1.
[0151] For the purposes of the present invention, the degree of renal impairment in a patient is defined by the estimated glomerular filtration rate (eGFR) as follows:
[0152] Normal renal function (CKD stage 1): eGFR ≥ 90 mL / min / 1.73 m 2
[0153] Mild renal impairment (CKD stage 2): eGFR ≥ 60 to < 90 mL / min / 1.73 m 2
[0154] Moderate renal impairment (CKD stage 3): eGFR ≥ 30 to < 60 mL / min / 1.73 m 2
[0155] Severe renal impairment (CKD stage 4): eGFR ≥ 15 to < 30 mL / min / 1.73 m2
[0156] Renal failure (CKD stage 5): eGFR < 15 mL / min / 1.73 m 2
[0157] According to the present invention, moderate renal impairment can be further divided into two stages:
[0158] Moderate renal impairment (CKD 3A): eGFR ≥ 45 to < 60 mL / min / 1.73 m 2
[0159] Moderate B renal impairment (CKD 3B): eGFR ≥ 30 to < 45 mL / min / 1.73 m 2
[0160] The term "KCCQ" refers to the Kansas City Cardiomyopathy Questionnaire. Health-related quality of life can be measured according to the KCCQ or the KCCQ-12. The KCCQ-12 is a validated, shorter version of the original 23-item KCCQ (Kansas City Cardiomyopathy Questionnaire). The purpose of this self-administered questionnaire is to assess physical limitations, symptoms (frequency, severity, and change over time), social limitations, self-efficacy, and quality of life in patients with HF.
[0161] The term "MLHFQ" refers to the Minnesota Living with Heart Failure Quality Questionnaire. Quality of life can be measured according to the MLHFQ, including its physical, emotional, social, and psychological dimensions. DETAILED DESCRIPTION
[0162] In addition to improvements in glycemic control and weight loss due to increased urinary glucose excretion, empagliflozin has demonstrated diuretic effects, reduced arterial stiffness, and direct vascular effects (Cherney et al., Cardiovasc Diabetol. 2014; 13:28; Cherney et al., Circulation. 2014; 129:587-597). EMPA-REG OUTCOME TMIn the study, it was confirmed that empagliflozin reduced the risk of cardiovascular death, heart failure hospitalization and total mortality in patients with type 2 diabetes and high cardiovascular risk (Zinman et al., N Engl J Med. 2015; 373: 2117-2128). It was observed that treatment with empagliflozin resulted in a decrease in blood pressure without clinically relevant changes in heart rate, thereby improving the heart rate-systolic pressure product (RPP), a surrogate marker for cardiac oxygen demand. In addition, in contrast to the increase observed with diuretics, empagliflozin was found to be unrelated to clinically relevant reflex-mediated sympathetic activation. It can be assumed that altered glucose and sodium gradients within the kidney can produce sympathetic inhibitory afferent renal nerve signals. Lack of sympathetic activation may contribute to the beneficial cardiovascular and renal distribution of empagliflozin (cardiorenal axis). Based on clinical and nonclinical studies, including mechanistic considerations, such as the effects of empagliflozin on human autonomic cardiovascular regulation, empagliflozin is used to treat and prevent certain diseases and conditions, especially chronic heart failure, acute heart failure and chronic kidney disease, described above and below.
[0163] The present invention relates to a method for treating chronic heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient. The present invention also relates to a method for reducing the risk of cardiovascular death in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient. The present invention further relates to a method for reducing the risk of hospitalization for heart failure in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient. The present invention also relates to a method for reducing the risk of cardiovascular death and hospitalization for heart failure in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient. According to one embodiment of the present invention, the risk of hospitalization for heart failure is the risk of first hospitalization for heart failure. According to another embodiment of the present invention, the risk of hospitalization for heart failure is the risk of recurrent hospitalization for heart failure. The present invention further relates to a method for reducing all-cause mortality in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient. In addition, the present invention relates to a method for reducing the risk of all-cause hospitalization in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient. According to one embodiment of the present invention, the risk of all-cause hospitalization is the risk of first all-cause hospitalization. According to another embodiment of the present invention, the risk of all-cause hospitalization is the risk of recurrent all-cause hospitalization. The present invention also relates to a method for reducing the risk of new-onset atrial fibrillation in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
[0164] The present invention also relates to a method for preventing, preventing or delaying the occurrence of chronic heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient. According to one embodiment of the present invention, a method for preventing the deterioration of chronic heart failure in a patient with NYHA class I chronic heart failure to NYHA class II, class III or class IV chronic heart failure is provided.
[0165] The present invention also relates to a method for treating, preventing, preventing or delaying the onset of acute heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient, especially wherein the patient is a patient with chronic heart failure.
[0166] The present invention also relates to a method for treating, preventing, protecting against, reducing the risk of, or delaying the onset of acute decompensated heart failure (ADHF) in a patient with chronic heart failure in need thereof, the method comprising administering empagliflozin to the patient.
[0167] In the methods according to the invention, the risk of an event, disease or condition is reduced when compared to a patient treated with a placebo according to the standard of care background medication. In one embodiment, the risk is reduced by 15% or more. In one embodiment, the risk is reduced by 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 25% or more, or 30% or more.
[0168] According to one embodiment of the present invention, the patient is a patient suffering from chronic heart failure according to NYHA class II, III or IV.
[0169] According to one aspect of this embodiment of the invention, the patient is a patient suffering from chronic heart failure according to NYHA class II or III.
[0170] According to another embodiment of the invention, the patient is a patient suffering from chronic heart failure according to NYHAI class.
[0171] According to one embodiment of the invention, the patient is a patient with chronic heart failure and preserved ejection fraction (HFpEF). For example, a patient with preserved ejection fraction exhibits an LVEF greater than 40% or even greater than 50%. According to a variant of this embodiment, a patient with chronic heart failure and preserved ejection fraction (HFpEF) exhibits an LVEF equal to or greater than 50%. According to another variant of this embodiment, the patient exhibits an LVEF in the range of 40% to 49%, also known as chronic heart failure with mid-range reduced ejection fraction (HFmrEF).
[0172] According to another embodiment of the invention, the patient is a patient suffering from chronic heart failure and reduced ejection fraction (HFrEF).For example, a patient with reduced ejection fraction exhibits a LVEF less than or equal to 40%, in particular less than 40%.
[0173] Therefore, according to one embodiment of the present invention, the present invention provides a method for treating chronic heart failure with preserved ejection fraction (HFpEF) in a patient in need thereof (e.g., a patient suffering from chronic heart failure according to NYHA class I, II, III or IV), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the degree of chronic heart failure in a patient suffering from chronic heart failure according to NYHA class II, III or IV is improved according to the NYHA classification. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0174] According to another embodiment, the present invention provides a method for treating chronic heart failure with reduced ejection fraction (HFrEF) in a patient in need thereof (e.g., a patient suffering from chronic heart failure according to NYHA class I, II, III, or IV), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the degree of chronic heart failure in a patient suffering from chronic heart failure according to NYHA class II, III, or IV is improved according to the NYHA classification. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient, or a type 2 diabetic patient, particularly a non-diabetic patient.
[0175] According to one embodiment, the present invention provides a method for reducing the risk of cardiovascular death in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0176] According to another embodiment, the present invention provides a method for reducing the risk of cardiovascular death in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0177] According to one embodiment, the present invention provides a method for reducing the risk of hospitalization for heart failure in a patient with chronic heart failure (e.g., according to NYHA class II, III, or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of first hospitalization for heart failure is reduced. According to another aspect of this embodiment, the risk of recurrent hospitalization for heart failure is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient, or a type 2 diabetic patient, particularly a non-diabetic patient.
[0178] According to another embodiment, the present invention provides a method for reducing the risk of hospitalization for heart failure in patients with chronic heart failure (e.g., according to NYHA class II, III, or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of first hospitalization for heart failure is reduced. According to another aspect of this embodiment, the risk of recurrent hospitalization for heart failure is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient, or a type 2 diabetic patient, particularly a non-diabetic patient.
[0179] According to one embodiment, the present invention provides a method for reducing the risk of cardiovascular death and heart failure hospitalization in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0180] According to another embodiment, the present invention provides a method for reducing the risk of cardiovascular death and heart failure hospitalization in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0181] According to one embodiment, the present invention provides a method for reducing the risk of all-cause mortality in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0182] According to one embodiment, the present invention provides a method for reducing the risk of all-cause mortality in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0183] According to one embodiment, the present invention provides a method for reducing the risk of all-cause hospitalization in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to another aspect of this embodiment, the risk of first all-cause hospitalization is reduced. According to another aspect of this embodiment, the risk of recurrent all-cause hospitalization is reduced. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0184] According to another embodiment, the present invention provides a method for reducing the risk of all-cause hospitalization in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of first all-cause hospitalization is reduced. According to another aspect of this embodiment, the risk of recurrent all-cause hospitalization is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0185] According to one embodiment, the present invention provides a method for reducing the risk of new-onset atrial fibrillation in a patient with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0186] According to another embodiment, the present invention provides a method for reducing the risk of new-onset atrial fibrillation in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and patients with reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0187] According to one embodiment, the present invention provides a method for improving the health-related quality of life and / or subjective functional capacity (particularly exercise capacity) of patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the health-related quality of life is measured by a questionnaire such as KCCQ or KCCQ-12. According to another aspect of this embodiment, the health-related quality of life or exercise capacity is measured by a walking test (e.g., a 6-minute walk test) or by maximum oxygen uptake (VO2max). The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0188] According to one embodiment, the present invention provides a method for improving the health-related quality of life and / or subjective functional capacity (particularly exercise capacity) of patients with chronic heart failure (e.g., according to NYHA II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA I grade. According to one aspect of this embodiment, the health-related quality of life is measured by a questionnaire (e.g., KCCQ or KCCQ-12). According to another aspect of this embodiment, the health-related quality of life or exercise capacity is measured by a walking test (e.g., a 6-minute walk test) or by maximum oxygen uptake (VO2max). The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0189] According to one embodiment, the present invention provides a method for treating, preventing, preventing, reducing the risk of acute decompensated heart failure (ADHF) in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and preserved ejection fraction (HFpEF), and delaying the occurrence of acute decompensated heart failure (ADHF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, in particular a non-diabetic patient.
[0190] According to another embodiment, the present invention provides a method for treating, preventing, preventing, reducing the risk of acute decompensated heart failure (ADHF) in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and reduced ejection fraction (HFrEF), delaying the occurrence of acute decompensated heart failure (ADHF), and reducing the risk of new atrial fibrillation, the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a type 2 diabetic patient, particularly a non-diabetic patient.
[0191] According to one embodiment, the present invention provides a method for reducing the risk of new-onset type 2 diabetes in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of the present invention, the patient is a non-diabetic patient. According to another aspect of the present invention, the patient is a prediabetic patient.
[0192] According to one embodiment, the present invention provides a method for reducing the risk of new-onset type 2 diabetes in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one invention of the present invention, the patient is a non-diabetic patient. According to another aspect of the present invention, the patient is a prediabetic patient.
[0193] According to one embodiment, the present invention provides a method for reducing the risk of myocardial infarction in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of non-fatal myocardial infarction is reduced. According to one aspect of this embodiment, the risk of fatal myocardial infarction is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0194] According to one embodiment, the present invention provides a method for reducing the risk of myocardial infarction in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of non-fatal myocardial infarction is reduced. According to one aspect of this embodiment, the risk of fatal myocardial infarction is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0195] According to one embodiment, the present invention provides a method for reducing the risk of stroke in a patient with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of non-fatal stroke is reduced. According to one aspect of this embodiment, the risk of fatal stroke is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0196] According to one embodiment, the present invention provides a method for reducing the risk of stroke in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the risk of non-fatal stroke is reduced. According to one aspect of this embodiment, the risk of fatal stroke is reduced. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0197] According to one embodiment, the present invention provides a method for reducing the risk of any one of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (so-called 3-point MACE) in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0198] According to one embodiment, the present invention provides a method for reducing the risk of any one of cardiovascular death (including fatal stroke, fatal myocardial infarction and sudden death), non-fatal myocardial infarction (excluding silent myocardial infarction), non-fatal stroke (so-called 3 endpoints MACE) in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0199] According to one embodiment, the present invention provides a method for reducing the risk of any one of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (so-called 3 endpoints MACE) in patients with chronic heart failure (e.g., according to NYHA II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA I grade. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0200] According to one embodiment, the present invention provides a method for reducing the risk of any one of cardiovascular death (including fatal stroke, fatal myocardial infarction and sudden death), non-fatal myocardial infarction (excluding silent myocardial infarction), non-fatal stroke (so-called 3 endpoints MACE) in patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. According to one aspect of this embodiment, the patient suffers from chronic heart failure according to NYHA class I. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0201] According to one embodiment, the present invention provides a method for preventing, slowing down or reversing the progression of patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and preserved ejection fraction (HFpEF) to macroalbuminuria, the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the progression from microalbuminuria to macroalbuminuria is prevented, slowed down or reversed. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0202] According to one embodiment, the present invention provides a method for preventing, slowing down or reversing the progression of patients with chronic heart failure (e.g., according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF) to macroalbuminuria, the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the progression from microalbuminuria to macroalbuminuria is prevented, slowed down or reversed. The patient according to this embodiment is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0203] According to one embodiment, the present invention provides a method for improving renal function in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and preserved ejection fraction (HFpEF) or for renal protection in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and preserved ejection fraction (HFpEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the patient has mild, moderate or severe renal impairment. According to this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient. According to one aspect of this embodiment, the improvement of renal function or renal protection is a slowing down of the decline in eGFR, such as a slowing down of the progressive decline in eGFR or a slowing down of the natural progressive decline in eGFR. According to another aspect of this embodiment, the improvement of renal function or renal protection is diagnosed by an increase in eGFR.
[0204] According to one embodiment, the present invention provides a method for improving renal function in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and reduced ejection fraction (HFrEF) or for renal protection in patients with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and reduced ejection fraction (HFrEF), the method comprising administering empagliflozin to the patient. For example, the patient suffers from chronic heart failure according to NYHA class I. According to one aspect of this embodiment, the patient has mild, moderate or severe renal impairment. According to one aspect of this embodiment, the patient is, for example, a non-diabetic patient, a prediabetic patient or a patient with type 2 diabetes, particularly a non-diabetic patient. According to one aspect of this embodiment, the improvement of renal function or renal protection is a slowing down of the decline in eGFR, such as a slowing down of the progressive decline in eGFR or a slowing down of the natural progressive decline in eGFR. According to one aspect of this embodiment, the improvement of renal function or renal protection is diagnosed by an increase in eGFR.
[0205] According to one embodiment, the present invention provides a method for treating, preventing, preventing, reducing the risk of chronic kidney disease in patients diagnosed with chronic heart failure, delaying the occurrence of chronic kidney disease in patients diagnosed with chronic heart failure, and / or delaying the progression of chronic kidney disease in patients diagnosed with chronic heart failure, the method comprising administering empagliflozin to the patient. In particular, the embodiment at this time relates to a method for treating and / or delaying the progression of chronic kidney disease in patients diagnosed with chronic heart failure, the method comprising administering empagliflozin to the patient. According to another aspect of this embodiment, the patient is a patient with stage 2 chronic kidney disease. According to one aspect of this embodiment, the patient is a patient with stage 3 (including stage 3a and / or stage 3b) chronic kidney disease. According to another aspect of this embodiment, the patient is a patient with stage 4 chronic kidney disease. According to one aspect of this embodiment, the patient is a patient with stage 3 (including stage 3a and / or stage 3b) or stage 4 chronic kidney disease, and a patient with chronic heart failure (e.g., according to NYHA class II, class III or class IV) and ejection fraction preservation (HFpEF). According to another aspect of this embodiment, the patient is a patient with stage 2 chronic kidney disease. According to another aspect of this embodiment, the patient is a patient with stage 3 (including stage 3a and / or stage 3b) or stage 4 chronic kidney disease, and a patient with chronic heart failure (e.g. according to NYHA class II, III or IV) and reduced ejection fraction (HFrEF). The patient according to this embodiment (including all aspects of this embodiment) is, for example, a non-diabetic patient, a pre-diabetic patient or a patient with type 2 diabetes, in particular a non-diabetic patient.
[0206] According to another embodiment, the present invention provides a method for treating, preventing, preventing, reducing the risk of chronic kidney disease in patients with undiagnosed chronic heart failure, delaying the occurrence of chronic kidney disease in patients with undiagnosed chronic heart failure, and / or delaying the progression of chronic kidney disease in patients with undiagnosed chronic heart failure, the method comprising administering empagliflozin to the patient, wherein the patient is a non-diabetic patient. In particular, this embodiment relates to a method for treating and / or delaying the progression of chronic kidney disease in a patient. According to one aspect of this embodiment, the patient is a patient with stage 3 (including stage 3a and / or stage 3b) chronic kidney disease. According to another aspect of this embodiment, the patient is a patient with stage 4 chronic kidney disease.
[0207] In one embodiment, the present invention provides a method for treating, preventing, arresting or delaying the occurrence of:
[0208] - New onset of albuminuria,
[0209] - Progression from analbuminuria to microalbuminuria or macroalbuminuria,
[0210] - Concomitant eGFR (based on the Modification of Diet in Renal Disease (MDRD) formula) ≤ 45 mL / min / 1.73 m 2 , serum creatinine doubled,
[0211] - Sustained decrease in eGFR (CKD-EPI) ≥30%, ≥40%, ≥50%, or ≥57%, particularly ≥
[0212] 40% sustained decrease in eGFR (CKD-EPI),
[0213] - Baseline eGFR ≥30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 15 mL / min / 1.73 m 2 ,
[0214] - Baseline eGFR <30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 ,
[0215] - Requires continuous renal replacement therapy,
[0216] - Requires long-term dialysis treatment,
[0217] -Need a kidney transplant,
[0218] - Death due to kidney disease, or
[0219] - Baseline eGFR ≥30 mL / min / 1.73 m 2Patients with a composite sustained decrease in eGFR (CKD-EPI) ≥40%, or a sustained eGFR (CKD-EPI) <15 mL / min / 1.73 m 2 ,and
[0220] Baseline eGFR <30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 ,or
[0221] - Baseline eGFR ≥30 mL / min / 1.73 m 2 Patients with a composite sustained decrease in eGFR (CKD-EPI) ≥40%, or a sustained eGFR (CKD-EPI) <15 mL / min / 1.73 m 2 ,
[0222] Baseline eGFR <30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 ,
[0223] requiring long-term dialysis treatment, and
[0224] Need a kidney transplant.
[0225] In a patient diagnosed with chronic heart failure, the method comprises administering empagliflozin to the patient. According to one aspect of this embodiment, the patient is a patient with chronic heart failure (e.g., according to NYHA Class I, Class II, Class III, or Class IV) and a preserved ejection fraction (HFpEF). According to another aspect of this embodiment, the patient is a patient with chronic heart failure (e.g., according to NYHA Class I, Class II, Class III, or Class IV) and a reduced ejection fraction (HFrEF). The patient according to this embodiment (including various aspects of this embodiment) is, for example, a non-diabetic patient, a prediabetic patient, or a patient with type 2 diabetes, particularly a non-diabetic patient.
[0226] In the method according to the invention, empagliflozin is optionally administered to the patient in combination with one or more other therapeutic substances.
[0227] According to one embodiment of the method described above and below, the patient is a patient with elevated BNP or elevated plasma NT-proBNP. For example, the patient has an elevated BNP equal to or greater than 75 pg / mL (NT-proBNP ≥ 300 pg / mL), or equal to or greater than 100 pg / mL (NT-proBNP ≥ 400 pg / mL), or equal to or greater than 150 pg / mL (NT-proBNP ≥ 600 pg / mL), or equal to or greater than 225 pg / mL (NT-proBNP ≥ 900 pg / mL).
[0228] According to another embodiment of the method described above and below, the patient is a patient hospitalized for heart failure within the past 9 months, in particular a patient hospitalized for heart failure within the past 9 months and has elevated BNP or NT-proBNP.
[0229] In one embodiment of the method described above and below, the patient is a patient with reduced ejection fraction (HFrEF) with an ejection fraction EF ≥ 36% to ≤ 40% and an elevated NT-proBNP ≥ 2500 pg / mL for patients without atrial fibrillation or an elevated NT-proBNP ≥ 5000 pg / mL for patients with atrial fibrillation.
[0230] In one embodiment of the method described above and below, the patient is a patient with reduced ejection fraction (HFrEF) with an ejection fraction EF ≥ 31% to ≤ 35% and an elevated NT-proBNP ≥ 1000 pg / mL for patients without atrial fibrillation or an elevated NT-proBNP ≥ 2000 pg / mL for patients with atrial fibrillation.
[0231] In one embodiment of the methods described above and below, the patient is a patient with reduced ejection fraction (HFrEF) with an ejection fraction ≤ 30% and an elevated NT-proBNP ≥ 600 pg / mL for patients without atrial fibrillation or an elevated NT-proBNP ≥ 1200 pg / mL for patients with atrial fibrillation.
[0232] According to one embodiment of the method described above and below, the patient is a patient with normal renal function or with mild renal impairment or with moderate renal impairment or with severe renal impairment. According to this embodiment, the patient has a renal function equal to or greater than 20 mL / min / 1.73 m 2 eGFR.
[0233] According to one embodiment of the method described above and below, the patient is a patient with normal renal function or with mild renal impairment or with moderate renal impairment. According to this embodiment, the patient has a renal function equal to or greater than 30 mL / min / 1.73 m2 eGFR.
[0234] According to another embodiment of the method described above and below, the patient is a patient with normal renal function or with mild renal impairment or with moderate A renal impairment (CKD 3A). According to this embodiment, the patient has a renal function equal to or greater than 45 mL / min / 1.73 m 2 eGFR.
[0235] According to another embodiment of the method described above or below, the patient is a patient with normal renal function or mild renal impairment. According to this embodiment, the patient has a renal function equal to or greater than 60 mL / min / 1.73 m 2 eGFR.
[0236] According to another embodiment of the method described above and below, the patient is a patient with moderate renal impairment (CKD3A). According to this embodiment, the patient has a renal function equal to or greater than 45 and less than 60 mL / min / 1.73 m 2 eGFR.
[0237] According to another embodiment of the method described above and below, the patient is a patient with moderate B renal impairment (CKD3B). According to this embodiment, the patient has a renal function equal to or greater than 30 and less than 45 mL / min / 1.73 m 2 eGFR.
[0238] According to one embodiment of the methods described above and below, the patient is a non-diabetic patient, a pre-diabetic patient, a patient with type 2 diabetes or a patient with type 1 diabetes.
[0239] According to another embodiment of the methods described above and below, the patient is a non-diabetic patient, a pre-diabetic patient, or a type 2 diabetic patient.
[0240] According to another embodiment of the method described above and below, the patient is a prediabetic patient. According to one aspect of the invention, the patient has an HbA1c greater than or equal to 5.7% and less than 6.5%.
[0241] According to another embodiment of the method described above and below, the patient is a pre-diabetic or non-diabetic patient. According to one aspect of this embodiment, the patient has an HbA1c of less than 6.5%.
[0242] According to another embodiment of the method described above and below, the patient is a non-diabetic patient. According to one aspect of this embodiment, the patient has an HbA1c of less than 5.7%.
[0243] According to another aspect, the non-diabetic patient does not show impaired glucose tolerance (IGT), ie, the patient shows normal glucose tolerance, for example, a 2-hour postprandial blood glucose or plasma glucose (PG) concentration of less than 140 mg / dl (7.78 mmol / L).
[0244] According to another aspect, the non-diabetic patient does not show impaired fasting glucose (IFG), ie the patient shows normal fasting glucose, for example, a fasting blood glucose (FPG) concentration of less than 100 mg / dl, ie less than 5.6 mmol / l.
[0245] In particular, non-diabetic patients do not show impaired fasting glucose (IFG) and do not show impaired glucose tolerance (IGT), that is, patients show normal glucose tolerance and normal glucose tolerance. For example, the fasting blood glucose (FPG) concentration is less than 100 mg / dl, i.e., less than 5.6 mmol / l, and the blood glucose or plasma glucose (PG) concentration 2 hours after a meal is less than 140 mg / dl (7.78 mmol / L).
[0246] According to one embodiment of the method described above and below, empagliflozin is administered to the patient in a dosage range of 1 to 25 mg per day, for example, 1 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg or 25 mg per day. The administration of empagliflozin can be performed once or twice a day, most preferably once a day. For example, the dosage administered once a day is 10 mg or 25 mg. The preferred route of administration is oral administration.
[0247] According to a specific aspect of the present invention, empagliflozin is administered to the patient at a dose of 10 mg per day.
[0248] According to another specific aspect of the present invention, empagliflozin is administered to the patient at a dose of 25 mg per day.
[0249] Preferably, empagliflozin is orally administered to the patient once daily.
[0250] In one embodiment, a patient in the sense of the present invention may include a patient with chronic heart failure who has not been previously treated with a drug for the chronic heart failure (heart-failure-drug-naive patient). Thus, in one embodiment, the treatments described herein can be used in heart failure-naive patients.
[0251] In another embodiment, patients in the sense of the present invention may include patients with chronic heart failure and prediabetes or type 2 diabetes (T2DM) who have not previously been treated with antidiabetic drugs (T2DM-untreated patients). Therefore, in one embodiment, the treatment described in the present application can be used for T2DM-untreated patients.
[0252] In addition, the method according to the invention is particularly suitable for treating patients with chronic heart failure and insulin dependence, that is, patients who are treated with insulin or insulin derivatives or insulin substitutes or preparations containing insulin or its derivatives or substitutes or who will be treated or need to be treated in other ways. These patients include patients with type 2 diabetes and patients with type 1 diabetes.
[0253] Furthermore, it may be found that the administration of the pharmaceutical composition according to the invention results in no risk or in a low risk of hypoglycemia.Thus, the treatment or prevention according to the invention may also be beneficial to those patients who exhibit or have an increased risk of hypoglycemia.
[0254] By administering empagliflozin, excess blood sugar is excreted through the patient's urine based on the SGLT2 inhibitory activity, which may result in no weight gain or even a reduction in weight in the patient. Therefore, the method according to the present invention is advantageously applicable to those patients with chronic heart failure who are diagnosed with one or more of the following conditions selected from the group consisting of overweight and obesity, in particular class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity. In addition, the method according to the present invention is advantageously applicable to those patients who are contraindicated for weight gain.
[0255] When the present invention refers to patients in need of treatment and prevention, it mainly relates to human treatment and prevention, but the pharmaceutical composition can also be used in veterinary medicine of mammals accordingly. In the context of the present invention, adult patients are preferably people of 18 years of age or older. Likewise, in the context of the present invention, patients are adolescents, i.e. people of 10 to 17 years of age, preferably people of 13 to 17 years of age.
[0256] According to one embodiment of the present invention, empagliflozin is administered to the patient in combination with one or more other therapeutic substances. The combined administration may be performed simultaneously, separately or sequentially.
[0257] In one aspect of this embodiment of the invention, the one or more other therapeutic substances are selected from active substances suitable for treating chronic heart failure, anti-diabetic substances, active substances for lowering total cholesterol, LDL-cholesterol, non-HDL cholesterol and / or Lp(a) levels in the blood, active substances for increasing HDL cholesterol levels in the blood, active substances for lowering blood pressure, active substances suitable for treating atherosclerosis and obesity, antiplatelet agents, anticoagulants, and endothelial protectors.
[0258] In one embodiment, the active substance indicated for the treatment of chronic heart failure is selected from angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor neprilysin inhibitors (ARNi), beta-blockers, aldosterone antagonists (MRA), digoxin, ivabradine and diuretics.
[0259] In one embodiment, the antidiabetic substance is selected from metformin, sulfonylureas, nateglinide, repaglinide, PPAR-γ agonists, alpha-glucosidase inhibitors, insulin and insulin analogs, GLP-1 and GLP-1 analogs and DPP-4 inhibitors.
[0260] In one embodiment, the patient receives standard care, which includes medications and / or devices adapted for patients with heart failure (e.g., chronic or acute heart failure). In one aspect, the patient, particularly a patient diagnosed with HFrEF, has or receives a device selected from the group consisting of an ICD (implantable cardioverter defibrillator) and a CRT (cardiac resynchronization therapy), such as a CRT-P (CRT pacemaker) and a CRT-D (CRT combination pacemaker and defibrillator).
[0261] In one embodiment, the patient receives standard care drugs adapted for patients with chronic heart failure. In one aspect of this embodiment, empagliflozin is administered to the patient in combination with one or more other therapeutic substances adapted for treating chronic heart failure. For example, empagliflozin is administered in combination with one or more active substances selected from the following: angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, diuretics, angiotensin receptor neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists and ivabradine. According to this aspect of the embodiment, the patient is, for example, a non-diabetic patient or a prediabetic patient.
[0262] In one aspect of this embodiment, the amount, dosage and / or regimen of the drug used to treat chronic heart failure is reduced in the patient while continuing to administer empagliflozin. For example, the dose of one or more diuretics administered to the patient can be reduced while continuing to administer empagliflozin.
[0263] Examples of angiotensin II receptor blockers (ARBs) are telmisartan, candesartan, valsartan, losartan, irbesartan, olmesartan, azilsartan, and eprosartan; dosages of some of these drugs are as follows:
[0264] Candesartan (Atacand), 4 mg, 8 mg, 16 mg, or 32 mg candesartan cilexetil
[0265] Eprosartan (Teveten), 400 mg or 600 mg
[0266] Irbesartan (Avapro), 75 mg, 150 mg, or 300 mg
[0267] Losartan (Cozaar), 25 mg, 50 mg, or 100 mg losartan potassium
[0268] Telmisartan (Micardis), 40 mg or 80 mg
[0269] Telmisartan (Micardis HCT), telmisartan and hydrochlorothiazide 40mg / 12.5mg each,
[0270] 80 mg / 12.5 mg and 80 mg / 25 mg
[0271] Telmisartan / amlodipine (Twynsta), 40 mg / 5 mg each of telmisartan and amlodipine,
[0272] 40 mg / 10 mg, 80 mg / 5 mg, and 80 mg / 10 mg
[0273] Valsartan (Diovan), 40 mg, 80 mg, 160 mg, or 320 mg valsartan
[0274] Examples of angiotensin converting enzyme (ACE) inhibitors are benazepril, captopril, ramipril, lisinopril, moexipril, cilazapril, quinapril, captopril, enalapril, benazepril, perindopril, fosinopril and trandolapril. Doses of some of these drugs are as follows:
[0275] Benazepril (Lotensin), 5 mg, 10 mg, 20 mg, and 40 mg orally
[0276] Captopril (Capoten), taken orally as a scored tablet of 12.5 mg, 25 mg, 50 mg, and 100 mg
[0277] Enalapril (Vasotec), 2.5 mg, 5 mg, 10 mg, and 20 mg oral tablets
[0278] Fosinopril (Monopril), 10 mg, 20 mg, and 40 mg tablets for oral administration
[0279] Lisinopril (Prinivil, Zestril), 5 mg, 10 mg, and 20 mg tablets for oral administration
[0280] Moexipril (Univasc), 7.5 mg and 15 mg orally
[0281] Perindopril (Aceon), available orally in 2 mg, 4 mg, and 8 mg strengths
[0282] Quinapril (Accupril), 5 mg, 10 mg, 20 mg, and 40 mg of quinapril, taken orally
[0283] Ramipril (Altace), 1.25 mg, 2.5 mg, 5 mg, 10 mg
[0284] Trandolapril (Mavik), 1 mg, 2 mg, or 4 mg of trandolapril administered orally
[0285] Examples of beta-blockers are acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, propranolol, timolol and carvedilol; dosages of some of these drugs are as follows:
[0286] Acebutolol (Sectral), 200 or 400 mg of acebutolol as the hydrochloride salt
[0287] Atenolol (Tenormin), 25, 50, and 100 mg tablets for oral administration
[0288] Betaxolol (Kerlone), 10 mg and 20 mg tablets for oral administration
[0289] Bisoprolol / hydrochlorothiazide (Ziac), 2.5 / 6 mg, 5 / 6.25 mg, 10 / 6.25 mg
[0290] Bisoprolol (Zebeta), 5 mg and 10 mg tablets for oral administration
[0291] Metoprolol (Lopressor, Toprol XL), 50 mg and 100 mg tablets for oral administration and 5 mL ampoule for intravenous administration
[0292] Propranolol (Inderal), 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg tablets for oral administration
[0293] Timolol (Blocadren), 5 mg, 10 mg, or 20 mg timolol maleate orally
[0294] Examples of aldosterone antagonists are spironolactone, eplerenone, canrenone, and fineronone; dosages for some of these drugs are as follows:
[0295] Spironolactone (eg, Aldactone), 25 or 50 mg once a day or every other day,
[0296] Eplerenone (eg, Inspra), 25 or 50 mg once daily.
[0297] Examples of diuretics are bumetanide, hydrochlorothiazide, chlortalidon, chlorothiazide, hydrochlorothiazide, xipamide, indapamide, furosemide, piretanide, torasemide, spironolactone, eplerenone, amiloride and triamterene; for example, these drugs are thiazide diuretics such as chlorthalidone, HCT, loop diuretics such as furosemide, torasemide or potassium-sparing diuretics such as eplerenone, or combinations thereof; the dosages of some of these drugs are as follows:
[0298] Amiloride (Midamor), 5 mg of anhydrous amiloride HCl
[0299] Bumetanide (Bumex), available as scored tablets, 0.5 mg (light green), 1 mg (yellow), and 2 mg (pink) for oral administration
[0300] Chlorothiazide (Diuril),
[0301] Chlorthalidone (Hygroton),
[0302] Furosemide (Lasix)
[0303] Hydrochlorothiazide (Esidrix, Hydrodiuril)
[0304] Indapamide (Lozol) and spironolactone (Aldactone)
[0305] Eplerenone (Inspra)
[0306] An example of an angiotensin receptor neprilysin inhibitor (ARNi) is the combination of valsartan and sacubitril (Entresto).
[0307] Inhibit cardiac pacemaker I f An example of an electric current is ivabradine (Procoralan, Corlanor).
[0308] Examples of calcium channel blockers are amlodipine, nifedipine, nitrendipine, nisoldipine, nicardipine, felodipine, lacidipine, lercanipidine, manidipine, isradipine, nilvadipine, verapamil, gallopamil and diltiazem.
[0309] Examples of drugs that lower blood pressure include angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and calcium channel blockers.
[0310] In another aspect of this embodiment, the patient is a patient with type 2 diabetes, and empagliflozin is administered to the patient with a combination of one or more active substances adapted to treat chronic heart failure and a combination of one or more antidiabetic substances. Antidiabetic substances include metformin, sulfonylureas, nateglinide, repaglinide, PPARγ agonists, α-glucosidase inhibitors, insulin and insulin analogs, GLP-1 and GLP-1 analogs, and DDP-4 inhibitors. Examples thereof are metformin and DDPIV inhibitors, such as sitagliptin, saxagliptin, and linagliptin. Active substances adapted to treat chronic heart failure include angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, and diuretics.
[0311] Therefore, according to one aspect of the method of the invention, empagliflozin is administered to a patient in combination with linagliptin. The patient according to this aspect is in particular a patient with type 2 diabetes. A preferred dosage is, for example, 10 mg empagliflozin once daily and 5 mg linagliptin once daily.
[0312] Therefore, according to another aspect of the method of the invention, empagliflozin is administered to a patient in combination with metformin hydrochloride. The patient according to this aspect is in particular a patient with type 2 diabetes. A preferred dosage is, for example, 10 mg empagliflozin once daily or 5 mg empagliflozin twice daily and 500 mg, 850 mg or 1000 mg metformin hydrochloride twice daily.
[0313] In one aspect of this embodiment, the amount, dosage and / or regimen of the drug used to treat chronic heart failure is reduced in the patient while continuing to administer empagliflozin. In another aspect of this embodiment, the amount, dosage and / or regimen of the drug used to treat type 2 diabetes is reduced in the patient while continuing to administer empagliflozin. In another aspect of this embodiment, the amount, dosage and regimen of the drug used to treat type 2 diabetes and the amount, dosage and regimen of the drug used to treat chronic heart failure are reduced in the patient while continuing to administer empagliflozin.
[0314] According to one example of this aspect, empagliflozin is administered in combination with one or more active substances selected from the group consisting of angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists and diuretics, angiotensin receptor neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists and ivabradine.
[0315] Examples of active substances in the above groups are known to those skilled in the art including their dosage strengths, administration regimens and formulations.
[0316] In the context of the present invention, the term metformin includes metformin hydrochloride in the form of an immediate release formulation, a delayed release formulation or a sustained release formulation. The dosage of metformin hydrochloride administered to a patient is particularly 500 mg to 2000 mg per day, for example 750 mg, 1000 mg, 1500 mg and 2000 mg per day.
[0317] Empagliflozin and metformin can be administered separately in two different dosage forms or in combination in one dosage form. The combined dosage form of empagliflozin and metformin as an immediate release formulation is described in WO 2011 / 039337 and is known, for example, as Combination dosage forms of empagliflozin and metformin, wherein empagliflozin is part of an immediate release formulation and metformin is part of a delayed release formulation, are described in WO 2012 / 120040 and WO 2013 / 131967.
[0318] The preferred dose of linagliptin administered to a patient is 5 mg per day.
[0319] Empagliflozin and linagliptin can be administered separately in two different dosage forms or in combination in one dosage form. The combined dosage form of empagliflozin and linagliptin is described in WO 2010 / 092124 and is known, for example, as
[0320] In the present invention it is to be understood that the combination, composition or combined administration according to the invention may envisage simultaneous, sequential or separate administration of the active components or ingredients.
[0321] In this case, "combination" or "combined" within the meaning of the present invention may include, but is not limited to, fixed and non-fixed (e.g., free) forms (including kits) and uses, such as simultaneous, sequential or separate use of the components or ingredients.
[0322] The combined administration of the present invention can be carried out by administering the active components or ingredients together, for example, in a single formulation or dosage form or in two separate formulations or dosage forms, and the active components or ingredients are administered simultaneously. Alternatively, administration can be carried out by sequentially, for example, successively administering the active components or ingredients in two separate formulations or dosage forms.
[0323] For the combination therapy of the present invention, the active components or ingredients can be administered separately (which means that they are formulated separately) or co-formulated (which means that they are configured into the same preparation or the same dosage form). Therefore, the administration of one component of the combination of the present invention can be carried out before, simultaneously or after the administration of the other components of the combination.
[0324] Unless otherwise specified, combination therapy may refer to first-line, second-line, or third-line therapy, or to initial therapy or to an add-on combination or alternative therapy.
[0325] The method according to the present invention is particularly suitable for long-term treatment or prevention of diseases and / or disorders described in the context. The term "long-term" as used in the context indicates that the treatment or application of the patient is in a time period longer than 12 weeks, preferably longer than 25 weeks, even more preferably longer than 1 year.
[0326] The pharmaceutical composition comprising empagliflozin according to the present invention can be formulated for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration in liquid or solid form or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred. The pharmaceutical composition can be formulated in the form of tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chewable tablets, lozenges, effervescent tablets, drops, suspensions, instant tablets, oral fast dispersible tablets, etc. The pharmaceutical composition and dosage form preferably contain one or more pharmaceutically acceptable carriers, which must be "acceptable" in the sense that they are compatible with the other ingredients of the formulation and harmless to the recipient. Examples of pharmaceutically acceptable carriers are known to those skilled in the art.
[0327] The pharmaceutical compositions and methods according to the present invention show beneficial effects in treating and preventing those diseases and conditions described above. For example, beneficial effects can be seen in terms of efficacy, dosage strength, dosage frequency, pharmacodynamic properties, pharmacokinetic properties, fewer side effects, convenience, compliance, etc.
[0328] Methods for preparing empagliflozin are known to those skilled in the art. Advantageously, the compounds according to the invention can be prepared using synthetic methods described in the literature, including the patent applications cited above. Preferred preparation methods are described in WO 2006 / 120208 and WO 2007 / 031548. Regarding empagliflozin, advantageous crystalline forms are described in international patent application WO2006 / 117359, which is hereby incorporated into the present application in its entirety.
[0329] Other embodiments, features and advantages of the present invention may become apparent from the following examples.The following examples are intended to illustrate the principles of the present invention without limiting it.
[0330] Example
[0331] Example 1: Treatment of patients with chronic heart failure and HFrEF
[0332] The long-term effects of treatment with empagliflozin on cardiovascular death and hospitalization for heart failure and other parameters in relevant populations of patients with chronic heart failure and reduced ejection fraction were studied as follows:
[0333] Patients with chronic heart failure and symptoms according to NYHA II, III or IV and reduced ejection fraction (LVEF less than or equal to 40%) and increased BNP (or increased NT-proBNP) are treated with empagliflozin (optionally in combination with one or more other active substances, such as those described herein) long-term (e.g., approximately 20 to 38 months per patient) and compared with patients treated with placebo according to the background standard of care medication.
[0334] Empagliflozin is administered orally once daily (e.g., 10 mg / day). Patients include non-diabetic patients, pre-diabetic patients, and patients with type 2 diabetes. Pre-diabetes is diagnosed if HbA1c is greater than or equal to 5.7% and less than 6.5%. If HbA1c is less than 5.7%, the individual is a non-diabetic patient. The patient's LVEF is less than or equal to 40%.
[0335] Patients with elevated BNP (or elevated NT-proBNP) were defined as having one of the following:
[0336] - Elevated BNP ≥ 150 pg / mL or NT-proBNP ≥ 600 pg / mL; or
[0337] - If the patient has been hospitalized for heart failure within the past 9 months, has an elevated BNP ≥ 100 pg / mL or NT-proBNP ≥ 400 pg / mL.
[0338] Patients with reduced ejection fraction may be included based on evidence of at least one of the following:
[0339] If the ejection fraction EF is ≥36% to ≤40%, the elevated NT-proBNP should be ≥2500 pg / mL for patients without atrial fibrillation or ≥5000 pg / mL for patients with atrial fibrillation.
[0340] If the ejection fraction EF is ≥31% to ≤35%, the elevated NT-proBNP should be ≥1000 pg / mL for patients without atrial fibrillation or ≥2000 pg / mL for patients with atrial fibrillation.
[0341] If the ejection fraction EF is ≤30%, the elevated NT-proBNP should be ≥600 pg / mL for patients without atrial fibrillation or ≥1200 pg / mL for patients with atrial fibrillation.
[0342] The study is event-driven and all randomized patients will continue on the trial until the number of patients who have reached the primary endpoint event is determined. The number of confirmed adjudicated primary endpoint events will be continuously monitored during the study.
[0343] Patients with cardiovascular risk factors are treated according to standard of care with or without cardiac device therapy (including ICD, CRT-D or CRT-P), for example, which includes treatment with a therapeutic agent selected from diuretics, ARNi, ACEi, ARB, statin, aspirin, beta-blocker, mineralocorticoid antagonist or ivabradine.
[0344] The patients in the study met the following criteria:
[0345] -Age over 18
[0346] - Diagnosis of heart failure (HF). HF included in this study was defined as a left ventricular ejection fraction (LVEF) (ideally obtained by echocardiography, but radionuclide ventriculography and angiography are acceptable) less than or equal to 40% (based on local readings). Ejection fraction values were preferably obtained within 6 months prior to randomization and after any myocardial infarction (MI) or other event that could affect ejection fraction.
[0347] - Heart failure (HF) symptoms (NYHA class II-IV)
[0348] - At least one of the following: elevated NT-proBNP ≥ 600 pg / mL, and / or elevated NT-proBNP ≥ 400 pg / mL if the patient has been hospitalized for heart failure within the last 9 months.
[0349] - Background treatment for heart failure if needed
[0350] - Background anti-diabetic therapy, if needed
[0351] - Body mass index (BMI) <45 kg / m 2
[0352] - eGFR ≥ 20 mL / min / 1.73 m 2 or eGFR ≥ 30 mL / min / 1.73 m 2
[0353] Time to cardiovascular death or hospitalization for heart failure was determined in patients with heart failure and reduced ejection fraction (based on the criteria described above) treated with empagliflozin (as 10 mg once daily) versus placebo.
[0354] Identify one or more of the following events:
[0355] - Time to first hospitalization for heart failure
[0356] - Slope of change from baseline in eGFR (CKD-EPI)
[0357] -Time to first sustained decrease of ≥40% eGFR (CKD-EPI)
[0358] -For baseline eGFR ≥30 mL / min / 1.73 m 2 The patient first experienced persistent
[0359] eGFR(CKD-EPI)<15mL / min / 1.73m 2 Time
[0360] - For baseline eGFR <30 mL / min / 1.73 m 2 The patient first experienced persistent
[0361] eGFR(CKD-EPI)<10mL / min / 1.73m 2 Time
[0362] -For baseline eGFR ≥30 mL / min / 1.73 m 2 , patients first experienced a sustained reduction of ≥ 40%
[0363] eGFR (CKD-EPI) or sustained eGFR (CKD-EPI) < 15 mL / min / 1.73 m 2 For baseline eGFR < 30 mL / min / 1.73 m 2 , patients with persistent eGFR (CKD-EPI) < 10
[0364] mL / min / 1.73m 2 The composite time.
[0365] -For baseline eGFR ≥30 mL / min / 1.73 m 2 , patients first experienced a sustained reduction of ≥ 40%
[0366] eGFR (CKD-EPI) or sustained eGFR (CKD-EPI) < 15 mL / min / 1.73 m 2 , and for baseline eGFR <30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 , or the composite time of requiring long-term dialysis treatment or requiring a kidney transplant,
[0367] - Time to cardiovascular death.
[0368] -Time to all-cause death
[0369] -Health-related quality of life (eg, as measured by the KCCQ or KCCQ-12)
[0370] -Time of new onset of type 2 diabetes in non-diabetic patients
[0371] - Time to recurrence of heart failure
[0372] -Changes in NYHA class
[0373] - Duration of all-cause hospitalization, including first and / or recurrent hospitalization
[0374] -Time of new onset of atrial fibrillation
[0375] - Time to non-fatal or fatal myocardial infarction
[0376] - Time to non-fatal or fatal stroke
[0377] - Time to composite cardiovascular death or myocardial infarction
[0378] - Time to composite cardiovascular death or stroke
[0379] - Time to any cardiovascular death (including fatal stroke, fatal myocardial infarction, and sudden death), non-fatal myocardial infarction, non-fatal stroke (so-called 3-endpoint MACE) - Change in eGFR
[0380] -Progression to macroalbuminuria (defined as albumin-to-creatinine ratio (ACR) ≥300 mg / g)
[0381] - Duration of need for long-term dialysis treatment
[0382] - When to receive a kidney transplant
[0383] - Composite of decreased eGFR, renal replacement therapy, or renal death
[0384] - Composite of decreased eGFR, renal replacement therapy, renal death, or cardiovascular death
[0385] - Composite of decreased eGFR, renal replacement therapy, renal death, or all-cause death
[0386] Example 2: Treatment of patients with chronic heart failure and HFpEF
[0387] The long-term effects of treatment with empagliflozin on cardiovascular death and hospitalization for heart failure and other parameters were studied in relevant populations of patients with chronic heart failure and preserved ejection fraction as follows:
[0388] Patients with chronic heart failure and symptoms according to NYHA II, III or IV and preserved ejection fraction (LVEF greater than 40% or greater than 50%) are treated long-term (e.g., approximately 20 to 38 months per patient) with empagliflozin (optionally in combination with one or more other active substances, such as those described herein) and compared with patients treated with placebo according to the background standard of care medication.
[0389] Empagliflozin is administered orally once daily (e.g., 10 mg / day). Patients include non-diabetic patients, pre-diabetic patients, and patients with type 2 diabetes. Pre-diabetes is diagnosed if HbA1c is greater than or equal to 5.7% and less than 6.5%. If HbA1c is less than 5.7%, the individual is a non-diabetic patient. The patient's LVEF is higher than 40%, particularly higher than 50%.
[0390] Patients included individuals with hospitalization for heart failure within the past 9 months and / or elevated BNP ≥ 75 pg / mL or NT-proBNP ≥ 300 pg / mL (for patients without atrial fibrillation (AF)) or elevated BNP > 225 pg / mL or NT-proBNP > 900 pg / mL (for patients with atrial fibrillation (AF)).
[0391] The study is event-driven and all randomized patients will continue on the trial until the number of patients who have reached the primary endpoint event is determined. The number of confirmed adjudicated primary endpoint events will be continuously monitored during the study.
[0392] Treat patients with cardiovascular risk factors according to standard of care, which includes symptomatic treatment and treatment of cardiovascular risk factors, including hypertension, diabetes, and dyslipidemia.
[0393] The patients in the study met the following criteria:
[0394] -Age over 18
[0395] - Diagnosis of heart failure (HF). HF included in this study is defined as a left ventricular ejection fraction (LVEF) (ideally obtained by echocardiography, but radionuclide ventriculography and angiography are acceptable) > 40% (based on local readings). Ejection fraction values are preferably obtained within 6 months prior to randomization and after any myocardial infarction (MI) or other event that could affect ejection fraction.
[0396] - Heart failure (HF) symptoms (NYHA class II-IV)
[0397] - Structural heart disease documented by echocardiography (left atrial enlargement or left ventricular hypertrophy)
[0398] - At least one of the following: hospitalization for heart failure within the past 9 months and / or elevated NT-proBNP (>300 pg / mL for patients without AF, or >900 pg / mL for patients with AF).
[0399] - Background treatment for heart failure if needed
[0400] - Background anti-diabetic therapy, if needed
[0401] - Body mass index (BMI) <45 kg / m 2
[0402] - eGFR ≥ 20 mL / min / 1.73 m 2 or eGFR ≥ 30 mL / min / 1.73 m 2
[0403] Time to cardiovascular death or hospitalization for heart failure was determined in patients with heart failure with preserved ejection fraction (based on the criteria described above) treated with empagliflozin (e.g. 10 mg once daily) versus placebo.
[0404] Identify one or more of the following events:
[0405] - Time to first hospitalization for heart failure
[0406] - Slope of change from baseline in eGFR (CKD-EPI)
[0407] -Time to first sustained decrease of ≥40% eGFR (CKD-EPI)
[0408] -For baseline eGFR ≥30 mL / min / 1.73 m 2 The patient first experienced persistent
[0409] eGFR(CKD-EPI)<15mL / min / 1.73m 2 Time
[0410] - For baseline eGFR <30 mL / min / 1.73 m 2 The patient first experienced persistent
[0411] eGFR(CKD-EPI)<10mL / min / 1.73m 2 Time
[0412] -For baseline eGFR ≥30 mL / min / 1.73 m 2 , patients first experienced a sustained reduction of ≥ 40%
[0413] eGFR (CKD-EPI) or sustained eGFR (CKD-EPI) < 15 mL / min / 1.73 m 2 For baseline eGFR < 30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 The composite time.
[0414] -For baseline eGFR ≥30 mL / min / 1.73 m 2 , patients first experienced a sustained reduction of ≥ 40%
[0415] eGFR (CKD-EPI) or sustained eGFR (CKD-EPI) < 15 mL / min / 1.73 m 2 , and for baseline eGFR <30 mL / min / 1.73 m 2 , patients with sustained eGFR (CKD-EPI) < 10 mL / min / 1.73 m 2 or the composite time of needing long-term dialysis treatment or needing a kidney transplant.
[0416] - Time to cardiovascular death
[0417] -Time of death from all causes
[0418] -Health-related quality of life (eg, as measured by the KCCQ or KCCQ-12)
[0419] -Time to new onset of type 2 diabetes in non-diabetic patients
[0420] -Changes in NYHA class
[0421] - Duration of all-cause hospitalization, including first and / or recurrent hospitalization
[0422] -Time of new onset of atrial fibrillation
[0423] - Time to non-fatal or fatal myocardial infarction
[0424] - Time to non-fatal or fatal stroke
[0425] - Time to any cardiovascular death (including fatal stroke, fatal myocardial infarction, and sudden death), non-fatal myocardial infarction (excluding silent myocardial infarction), non-fatal stroke (so-called 3-endpoint MACE)
[0426] - Changes in eGFR
[0427] -Progression to macroalbuminuria (defined as albumin-to-creatinine ratio (ACR) ≥300 mg / g)
[0428] - Duration of need for long-term dialysis treatment
[0429] - When to receive a kidney transplant
[0430] - Composite of decreased eGFR, renal replacement therapy, or renal death
[0431] - Composite of decreased eGFR, renal replacement therapy, renal death, or cardiovascular death
[0432] - Composite of decreased eGFR, renal replacement therapy, renal death, or all-cause death
[0433] Health-related quality of life can be measured according to the KCCQ or KCCQ-12. The KCCQ-12 is a validated short version of the original 23-item KCCQ (Kansas City Cardiomyopathy Questionnaire). This self-administered questionnaire is designed to assess physical limitations, symptoms (frequency, severity, and change over time), social limitations, self-efficacy, and quality of life in patients with HF.
[0434] Example 3: Treatment of patients with chronic heart failure and HFrEF
[0435] The effects of treatment with empagliflozin on subjective functional capacity and other parameters in relevant groups of patients with chronic heart failure and reduced ejection fraction and frailty were studied as follows:
[0436] Patients with chronic heart failure and symptoms according to NYHA II, III or IV and reduced ejection fraction (LVEF less than or equal to 40%) and increased BNP (or increased NT-proBNP) and frailty are treated with empagliflozin (optionally in combination with one or more other active substances, such as those described herein) over a period of time (e.g., approximately 12 weeks per patient) and compared with patients treated with placebo according to background standard of care medication.
[0437] Empagliflozin is administered orally once daily (e.g., 10 mg / day). Patients include non-diabetic patients, pre-diabetic patients, and patients with type 2 diabetes. Pre-diabetes is diagnosed if HbA1c is greater than or equal to 5.7% and less than 6.5%. If HbA1c is less than 5.7%, the individual is a non-diabetic patient. The patient's LVEF is less than or equal to 40%.
[0438] Patients with elevated BNP (or elevated NT-proBNP) were defined as having one of the following:
[0439] - Elevated BNP ≥ 150 pg / mL or NT-proBNP ≥ 600 pg / mL; or
[0440] - Elevated BNP ≥100 pg / mL or NT-proBNP ≥400 pg / mL if the patient has been hospitalized for heart failure within the past 9 months.
[0441] Patients with reduced ejection fraction may be included based on evidence of at least one of the following:
[0442] If the ejection fraction EF is ≥36% to ≤40%, the elevated NT-proBNP should be ≥2500 pg / mL in patients without atrial fibrillation or ≥5000 pg / mL in patients with atrial fibrillation.
[0443] If the ejection fraction EF is ≥31% to ≤35%, the elevated NT-proBNP should be ≥1000 pg / mL in patients without atrial fibrillation or ≥2000 pg / mL in patients with atrial fibrillation.
[0444] If the ejection fraction EF is ≤30%, the elevated NT-proBNP should be ≥600 pg / mL in patients without atrial fibrillation or ≥1200 pg / mL in patients with atrial fibrillation.
[0445] Frail patients were included in the study, for example, if they reached a distance of less than 350 m in a 6-minute walk test.
[0446] At the end of each patient study period, subjective functional capacity, in particular exercise capacity, such as the 6-minute walk test, and further clinical parameters, such as the following, are investigated.
[0447] Patients with cardiovascular risk factors are treated according to standard of care with or without cardiac device therapy (including ICD, CRT-D or CRT-P), for example, which includes the use of a therapeutic agent selected from diuretics, ARNi, ACEi, ARB, statin, aspirin, beta-blocker, mineralocorticoid antagonist or ivabradine.
[0448] The patients in the study met the following criteria:
[0449] -Age over 18
[0450] - Diagnosis of heart failure (HF). HF included in this study was defined as a left ventricular ejection fraction (LVEF) (ideally obtained by echocardiography, but radionuclide ventriculography and angiography are acceptable) less than or equal to 40% (based on local readings). Ejection fraction values were preferably obtained within 6 months prior to randomization and after any myocardial infarction (MI) or other event that could affect ejection fraction.
[0451] - Heart failure (HF) symptoms (NYHA class II-IV)
[0452] - At least one of the following: elevated NT-proBNP ≥ 600 pg / mL and / or elevated NT-proBNP ≥ 400 pg / mL if the patient has been hospitalized for heart failure within the past 9 months.
[0453] - Weakness, as measured, for example, by a 6-minute walk test in which the patient reaches a distance of less than 350 meters.
[0454] - Background treatment for heart failure if needed
[0455] - Background anti-diabetic therapy, if needed
[0456] - Body mass index (BMI) <45 kg / m 2
[0457] - eGFR ≥ 20 mL / min / 1.73 m 2 or eGFR ≥ 30 mL / min / 1.73 m 2
[0458] At the end of each patient study period, e.g. 12 weeks, the subjective functional capacity, in particular exercise capacity, e.g. 6-minute walk test, is determined in patients with chronic heart failure and reduced ejection fraction (according to the criteria described above) treated with empagliflozin (e.g. 10 mg once daily) or placebo.
[0459] Identify one or more of the following events:
[0460] -Changes in NYHA class
[0461] -Health-related quality of life (eg, measured by KCCQ or KCCQ-12, MLHFQ, fatigue score, depression score, anxiety score, global assessment score)
[0462] - Change from baseline in biomarkers such as NT-proBNP
[0463] - Time to first hospitalization for heart failure
[0464] -Time to re-hospitalization for heart failure
[0465] Example 4: Treatment of frail patients with chronic heart failure and HFpEF
[0466] The effects of treatment with empagliflozin on subjective functional capacity and other parameters in relevant groups of patients with chronic heart failure and preserved ejection fraction and frailty were studied as follows:
[0467] Patients with chronic heart failure and symptoms according to NYHA II, III or IV and preserved ejection fraction (LVEF greater than 40% or greater than 50%) and frailty are treated with empagliflozin (optionally in combination with one or more other active substances, such as those described herein) over a period of time (e.g., approximately 12 weeks per patient) and compared with patients treated with placebo according to background standard of care medication.
[0468] Empagliflozin is administered orally once daily (e.g., 10 mg / day). Patients include non-diabetic patients, prediabetic patients, and patients with type 2 diabetes. Prediabetes is diagnosed if HbA1c is greater than or equal to 5.7% and less than 6.5%. If HbA1c is less than 5.7%, the individual is a non-diabetic patient. The patient's LVEF is higher than 40%, particularly higher than 50%.
[0469] Patients included individuals with hospitalization for heart failure within the past 9 months and / or elevated BNP ≥ 75 pg / mL or NT-proBNP ≥ 300 pg / mL (patients without atrial fibrillation (AF)) or elevated BNP > 225 pg / mL or NT-proBNP > 900 pg / mL (patients with atrial fibrillation (AF)).
[0470] Frail patients were included in the study, for example, if they reached a distance of less than 350 m in a 6-minute walk test.
[0471] At the end of each patient study period, subjective functional capacity, in particular exercise capacity, such as the 6-minute walk test, and further clinical parameters, such as the following, are investigated.
[0472] Patients with cardiovascular risk factors are treated according to standard of care, which includes symptomatic treatment and treatment of cardiovascular risk factors, including hypertension, diabetes, and dyslipidemia.
[0473] The patients in the study met the following criteria:
[0474] -Age over 18
[0475] - Diagnosis of heart failure (HF). HF included in this study is defined as a left ventricular ejection fraction (LVEF) (ideally obtained by echocardiography, but radionuclide ventriculography and angiography are acceptable) > 40% (based on local readings). Ejection fraction values are preferably obtained within 6 months prior to randomization and after any myocardial infarction (MI) or other event that could affect ejection fraction.
[0476] - Heart failure (HF) symptoms (NYHA class II-IV)
[0477] - Structural heart disease documented by echocardiography (left atrial enlargement or left ventricular hypertrophy)
[0478] - At least one of the following: hospitalization for heart failure within the past 9 months and / or elevated NT-proBNP (>300 pg / mL for patients without atrial fibrillation (AF), or >900 pg / mL for patients with atrial fibrillation (AF)).
[0479] - Weakness, as measured, for example, by a 6-minute walk test in which the patient reaches a distance of less than 350 meters.
[0480] - Background treatment for heart failure if needed
[0481] - Background anti-diabetic therapy, if needed
[0482] - Body mass index (BMI) <45 kg / m 2
[0483] - eGFR ≥ 20 mL / min / 1.73 m 2 or eGFR ≥ 30 mL / min / 1.73 m 2
[0484] At the end of a defined period of time, e.g. 12 weeks, subjective functional capacity, in particular exercise capacity, e.g. a 6-minute walk test, is determined in patients with heart failure and preserved ejection fraction (according to the criteria described above) treated with empagliflozin (e.g. 10 mg once daily) or placebo.
[0485] Identify one or more of the following events:
[0486] -Changes in NYHA class
[0487] -Health-related quality of life (eg, measured by KCCQ or KCCQ-12, MLHFQ, fatigue score, depression score, anxiety score, global assessment score)
[0488] - Change from baseline in biomarkers such as NT-proBNP
[0489] - Time to first hospitalization for heart failure
[0490] -Time to re-hospitalization for heart failure
[0491] Examples of pharmaceutical compositions and dosage forms
[0492] The following examples of solid pharmaceutical compositions and dosage forms for oral administration serve to more fully illustrate the invention without limiting it to the contents of the examples. Further examples of compositions and dosage forms for oral administration are described in WO 2010 / 092126. The term "active substance" means empagliflozin according to the invention, in particular its crystalline forms, described in WO 2006 / 117359 and WO 2011 / 039107.
[0493] Tablets comprising 2.5 mg, 5 mg, 10 mg or 20 mg of the active substance empagliflozin.
[0494] The amount of ingredients is provided in mg per film-coated tablet.
[0495]
[0496]
[0497] Details on the preparation of tablets, active pharmaceutical ingredients, excipients and film coating systems are described in WO 2010 / 092126, in particular in Examples 5 and 6 thereof, which are hereby incorporated in their entirety into the present application.
Claims
1. A method for treating, preventing, preventing or delaying the onset of chronic heart failure in a patient in need thereof, the method comprising administering empagliflozin to the patient.
2. A method for reducing the risk of cardiovascular death in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
3. A method for reducing the risk of hospitalization for heart failure in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
4. The method according to claim 3, wherein the risk of hospitalization for heart failure is the risk of first hospitalization for heart failure.
5. A method for reducing all-cause mortality in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
6. A method for reducing the risk of all-cause hospitalization in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
7. A method for reducing the risk of new onset atrial fibrillation in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
8. A method for treating, preventing, protecting against, reducing the risk of, or delaying the onset of acute heart failure in a patient in need thereof, including acute decompensated heart failure, comprising administering empagliflozin to the patient.
9. A method for treating, preventing, protecting against, reducing the risk of chronic kidney disease in a patient with chronic heart failure, delaying the onset of chronic kidney disease in a patient with chronic heart failure, and / or delaying the progression of chronic kidney disease in a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
10. A method for improving the health-related quality of life of a patient with chronic heart failure and / or the subjective functional capacity of a patient with chronic heart failure, the method comprising administering empagliflozin to the patient.
11. The method according to one or more of claims 1 to 10, wherein the patient is a patient suffering from chronic heart failure according to NYHA class II, III or IV.
12. The method according to one or more of claims 1 to 11, wherein the patient is a patient with preserved ejection fraction.
13. The method according to one or more of claims 1 to 11, wherein the patient is a patient with reduced ejection fraction.
14. The method according to one or more of claims 1 to 13, wherein the patient is a patient suffering from prediabetes, type 1 diabetes or type 2 diabetes.
15. The method according to one or more of claims 1 to 13, wherein the patient is a non-diabetic patient.
16. The method according to one or more of claims 1 to 15, wherein the patient has a blood pressure equal to or greater than 20 mL / min / 1.73 m 2 eGFR, or equal to or greater than 30 mL / min / 1.73 m 2 eGFR, or equal to or greater than 45 mL / min / 1.73 m 2 eGFR, or equal to or greater than 60 mL / min / 1.73 m 2 eGFR.
17. The method according to one or more of claims 1 to 16, wherein empagliflozin is administered in a dose ranging from 1 mg to 25 mg.
18. The method according to one or more of claims 1 to 17, wherein empagliflozin is administered to the patient in combination with one or more other therapeutic substances.
19. The method according to claim 18, wherein the one or more other therapeutic substances are selected from the following substances: active substances suitable for the treatment of chronic heart failure, antidiabetic substances, active substances for lowering the levels of total cholesterol, LDL-cholesterol, non-HDL-cholesterol and / or Lp(a) in the blood, active substances for increasing the level of HDL-cholesterol in the blood, active substances for lowering blood pressure, active substances suitable for the treatment of atherosclerosis or obesity, antiplatelet agents, anticoagulants, and endothelial protectors.
Citation Information
Patent Citations
Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
WO2005092877A1
CRYSTALLINE FORM OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
WO2006117359A1
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2006120208A1
Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
WO2007031548A2
Pharmaceutical composition comprising linagliptin and optionally a SGLT2 inhibitor, and uses thereof
WO2010092124A1
